Postmenopausal Women With Advanced Breast Cancer Clinical Trial
Official title:
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
- Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine
therapy in postmenopausal patients with advanced breast cancer who received previous
anti-estrogen treatment
- To investigate changes in blood drug concentrations and blood hormone kinetics.
- To investigate gene polymorphisms of CYP2A6, an enzyme involved in the metabolism of
letrozole
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00237211 -
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
|
Phase 2 | |
| Completed |
NCT00247663 -
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
|
Phase 2 |